Bradford Whitmer, DO
Gastroenterology · Saint Clair Shores, MINPI 1669636965
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $176,655 of the $205,971 with a category attached, or 85.8%. 29 manufacturers reported payments, led by AbbVie at 41.7% of the total. 2025 is the largest year on record at $54,336, 2.0 times the $26,729 reported in 2019. Among gastroenterology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 609 payments — averaging $338.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$86K
- Aimmune Therapeutics, Inc.$49K
- Nestle Healthcare Nutrition Inc.$26K
- Sanofi$20K
- E.r. Squibb & Sons, L.L.C.$17K
- Bristol Myers Squibb$3K
- plus $5K from 23 others
What the payments were for
- Consulting fees$7,0193%
- Speaking & faculty fees$176,65586%
- Travel & lodging$10,0075%
- Food & beverage$12,1866%
- Education$1040%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 217 | $85,875 |
| Aimmune Therapeutics, Inc. | 69 | $49,329 |
| Nestle Healthcare Nutrition Inc. | 38 | $26,032 |
| Sanofi | 19 | $19,568 |
| E.r. Squibb & Sons, L.L.C. | 13 | $17,140 |
| Bristol Myers Squibb | 12 | $2,863 |
| Medtronic | 19 | $1,442 |
| Johnson & Johnson(2 entities) | 50 | $1,039 |
| Pfizer | 43 | $615 |
| Takeda Pharmaceuticals U.S.A., Inc. | 44 | $506 |
| Gilead | 23 | $425 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $275 |
| Boston Scientific | 3 | $138 |
| Phathom Pharmaceuticals, Inc. | 2 | $117 |
| Intercept Pharmaceuticals, Inc. | 7 | $114 |
| Merck | 7 | $98 |
| QOL Medical, LLC | 8 | $90 |
| UCB, Inc. | 5 | $58 |
| Lilly USA, LLC | 3 | $55 |
| Ferring Pharmaceuticals Inc. | 3 | $37 |
| Endo Pharmaceuticals Inc. | 2 | $33 |
| Evoke Pharma, Inc. | 1 | $22 |
| Mylan Specialty L.p. | 1 | $21 |
| Genentech USA, Inc. | 1 | $18 |
| GSK | 1 | $18 |
| Capsovision, Inc. | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
| IBSA Pharma Inc. | 1 | $13 |
| Ambu Inc. | 1 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$205,971 in reported general payments places this provider in the 95th percentile of 497 gastroenterology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 47 | $1,277,176 |
| Humira(Cf) PenAdalimumab | 25 | $167,988 |
| CreonLipase/Protease/Amylase | 31 | $98,563 |
| ZenpepLipase/Protease/Amylase | 16 | $87,766 |
| XeljanzTofacitinib Citrate | 13 | $72,217 |
| Mesalamine | 40 | $37,223 |
| OzempicSemaglutide | 18 | $24,803 |
| MotegrityPrucalopride Succinate | 24 | $20,903 |
| LinzessLinaclotide | 18 | $17,406 |
| Dexlansoprazole DrDexlansoprazole | 18 | $7,579 |
| Budesonide EcBudesonide | 25 | $6,816 |
| TrulancePlecanatide | 13 | $6,770 |
| Colesevelam Hcl | 39 | $3,987 |
| Balsalazide Disodium | 22 | $3,979 |
| Budesonide DrBudesonide | 35 | $3,762 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $1,039 | $1,277,17647 claims |
| AbbVieCreon, Linzess | $85,875 | $115,96949 claims |
| Aimmune Therapeutics, Inc.Zenpep | $49,329 | $87,76616 claims |
| PfizerXeljanz | $615 | $72,21713 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $506 | $20,90324 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $275 | $6,77013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 497 gastroenterology providers in Michigan.
Other gastroenterology in Saint Clair Shores
- Leonid ShambanSaint Clair Shores$18K
- Kimberly BrownDetroit$733K
- Dilip MoonkaDetroit$611K
- Philip SchoenfeldAnn Arbor$539K
- Michelle Muza-MoonsAnn Arbor$481K
- Partha NandiTroy$377K
- Mohammed BarawiSt Clair Shores$193K
- Stuart GordonDetroit$178K
- Mohamad AlsibaeRoyal Oak$127K
- Allison SchulmanAnn Arbor$124K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.